SLC2A1 and neoplasm: Based on this mechanism, combined targeting of the GLUT1/NSUN2 axis with the small molecule inhibitor WZB117 and PD-L1 immune checkpoint blockade synergistically suppresses tumor evolution and reverses immune suppression, offering a potential strategy for therapy-resistant HCC (75).